Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 10/2005

01-10-2005 | Letter

Reply to comment on: Biason-Lauber A, Boehm B, Lang-Muritano M et al. (2005) Association of childhood type 1 diabetes mellitus with a variant of PAX4: possible link to beta cell regenerative capacity. Diabetologia 48:900–905

Authors: A. Biason-Lauber, B. Boehm, M. Lang-Muritano, B. R. Gauthier, T. Brun, C. B. Wollheim, E. J. Schoenle

Published in: Diabetologia | Issue 10/2005

Login to get access

Excerpt

To the Editor: Some concerns have been raised that the analytical methods we used for genotyping may be responsible for the striking differences observed in the distribution of the genotypes of the PAX4 A1168C SNP, which deviated from Hardy–Weinberg equilibrium (HWE). In our certified laboratory (ISO/IEC 17025, accreditation STS286) both genotyping methods used (RFLP and allelic discrimination) were validated as described below. …
Literature
1.
Biason-Lauber A, Boehm B, Lang-Muritano M et al (2005) Association of childhood type 1 diabetes mellitus with a variant of PAX4: possible link to beta cell regenerative capacity. Diabetologia 48:900–905CrossRefPubMed
2.
Rousset F, Raymond M (1995) Testing heterozygote excess and deficiency. Genetics 140:1413–1419PubMed
3.
Weitkamp LR, Tackels DC, Hunter AG, Holmes LB, Schwartz CE (1998) Heterozygote advantage of the MTHFR gene in patients with neural-tube defect and their relatives. Lancet 351:1554–1555CrossRefPubMed
4.
Nelson GW, Martin MP, Glasman D, Wade J, Trowsdale J, Carrington M (2004) Cutting edge: heterozygote advantage in autoimmune disease: hierarchy of protection/susceptibility conferred by HLA and killer Ig-like receptor combination in psoriatric arthritis. J Immunol 173:4273–4276PubMed
5.
Balloux F (2004) Heterozygote excess in small populations and the heterozygote-excess effective population size. Evolution Int J Org Evolution 58:1891–1900PubMed
6.
Correa PA, Gomez LM, Cadena J, Anaya JM (2005) Autoimmunity and tuberculosis: opposite association with TNF polymorphsim. J Rheumatol 32:219–224PubMed
7.
Shimajiri Y, Sanke T, Furuta H et al (2001) A missense mutation of Pax4 gene (R121W) is associated with type 2 diabetes in Japanese. Diabetes 50:2864–2869PubMed
8.
Dupont S, Vionnet N, Chevre JC et al No evidence of linkage or diabetes-associated mutations in the transcription factors BETA2/NEUROD1 and PAX4 in Type II diabetes in France. Diabetologia 42:480–484
9.
Paterson A (2005) Comment to Biason-Lauber A, Boehm B, Lang-Muritano M et al (2005) Association of childhood type 1 diabetes mellitus with a variant of PAX4: possible link to beta cell regenerative capacity. Diabetologia DOI 10.​1007/​s00125-005-1884-2
10.
Maier LM, Cooper JD, Walker N, Smyth DJ, Todd JA (2005) Comment to Biason-Lauber A, Boehm B, Lang-Muritano M et al (2005) Association of childhood type 1 diabetes mellitus with a variant of PAX4: possible link to beta cell regenerative capacity. Diabetologia DOI 10.​1007/​s00125-005-1906-0
11.
Brun T, Franklin I, St-Onge L et al (2004) The diabetes-linked transcription factor PAX4 promotes beta-cell proliferation and survival in rat and human islets. J Cell Biol 167:1123–1135CrossRefPubMed
12.
Metadata
Title
Reply to comment on: Biason-Lauber A, Boehm B, Lang-Muritano M et al. (2005) Association of childhood type 1 diabetes mellitus with a variant of PAX4: possible link to beta cell regenerative capacity. Diabetologia 48:900–905
Authors
A. Biason-Lauber
B. Boehm
M. Lang-Muritano
B. R. Gauthier
T. Brun
C. B. Wollheim
E. J. Schoenle
Publication date
01-10-2005
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 10/2005
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-005-1925-x

Other articles of this Issue 10/2005

Diabetologia 10/2005 Go to the issue

Article

Insulin-producing cells derived from human pancreatic non-endocrine cell cultures reverse streptozotocin-induced hyperglycaemia in mice

Article

Differential changes in brain glucose metabolism during hypoglycaemia accompany loss of hypoglycaemia awareness in men with type 1 diabetes mellitus. An [11C]-3-O-methyl-d-glucose PET study

Letter

Comment to: Zalutskaya A, Bornstein SR, Mokhort T, Garmaev D (2004) Did the Chernobyl incident cause an increase in type 1 diabetes mellitus incidence in children and adolescents? Diabetologia 47:147–148 (Letter)

Letter

Reply to comment on: Godsland IF, Jeffs JA, Johnston DG (2004) Loss of beta cell function as fasting glucose increases in the non-diabetic range. Diabetologia 47:1157–1166

Article

Expression and function of receptors for insulin-like growth factor-I and insulin in human coronary artery smooth muscle cells

Article

Islet transplantation outcomes in mice are better with fresh islets and exendin-4 treatment
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits